One of the most popular ADHD drugs may cause hallucinations and other psychotic symptoms

runawaybunny

Administrator
Staff member
adhd-drug.jpg

In the scientific article recently published in Scandinavian Journal of Child and Adolescent Psychiatry and Psychology, Erica Ramstad and others reviewed the existing evidence between various psychotic symptoms such as hallucinations, problems with concentration or anxiety with methylphenidate, a drug commonly prescribed as a treatment for attention deficit hyperactivity disorder (ADHD) and narcolepsy.

Methylphenidate is a stimulant that increases the activity of the central nervous system, helps to combat fatigue, improves attention and maintains alertness. Its medial use medical use began in 1960 and continues to grow since, reaching global consumption of 2.4 billion doses in 2013. Clinical studies confirmed safety and effectiveness of the drug and proved that its long-term usage reduces abnormalities in brain structure and function usually associated with ADHD syndrome.

Currently around around 5.3% children and adolescents worldwide suffer from ADHD condition. Psychostimulants, including methylphenidate, are first-choice drug treatment. Ramstad and others examined whether methylphenidate increases the risk of psychotic symptoms in children and adolescents affected with the illness. Although the amount and quality of existing data did not allow them to draw any strong conclusions, their research suggests that possible adverse symptoms may affect around 1.1% to 2.5% of ADHD patients treated with methylphenidate.

The article and its findings are of great importance for patients, physicians and caregivers who should be aware of possible adverse effects of the drug. In case of appearance of psychotic symptoms during the methylphenidate medication, clinicians should be able to address the problem, reduce or stop stimulant medication and ensure proper treatment.

Source: Exeley Inc.
Journal: Scandinavian Journal of Child and Adolescent Psychiatry and Psychology
Funder: Region Zealand Research Foundation, Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital
Related Journal Article: https://www.exeley.com/sj_child_adolescent_psychiatry_psychology/doi/10.21307/sjcapp-2018-003

This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ConductDisorders or its staff.
 

TerryJ2

Well-Known Member
Scary stuff. Do you know if there are followup studies on how long it took to return to baseline after stopping the medication? And do you know if the patients were vetted for any family members who had schizoaffective disorder or other hallucinogenic type disorders?
 
Top